ÎåÐÇÌåÓýÖ±²¥ Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- ÎåÐÇÌåÓýÖ±²¥ (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of ÎåÐÇÌåÓýÖ±²¥â€™ Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of ÎåÐÇÌåÓýÖ±²¥ common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company’s 2024 Inducement Plan.

The stock options have an exercise price equal to the closing price per share of ÎåÐÇÌåÓýÖ±²¥â€™ common stock as reported by Nasdaq on the grant date, and vest over four years, with 25 percent of the shares vesting on the first anniversary of the vesting commencement date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to each employee’s continued service with ÎåÐÇÌåÓýÖ±²¥ through the applicable vesting dates. The RSUs will vest in equal annual installments on each anniversary of the grant date, until the third anniversary of such date, subject to each employee’s continued service with ÎåÐÇÌåÓýÖ±²¥ through the applicable vesting dates.

ÎåÐÇÌåÓýÖ±²¥ is providing this information in accordance with Nasdaq Listing Rule 5635(c)4.

About ÎåÐÇÌåÓýÖ±²¥

ÎåÐÇÌåÓýÖ±²¥ is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. ÎåÐÇÌåÓýÖ±²¥ enzymes solve for real-world challenges associated with small molecule and nucleic acid therapeutics manufacturing. The Company is currently developing its proprietary ECO Synthesisâ„¢ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. ÎåÐÇÌåÓýÖ±²¥â€™ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit .

For More Information

Carrie McKim
(336) 608-9706


Source: ÎåÐÇÌåÓýÖ±²¥